Vaccitech to Present at the Jefferies Virtual Healthcare Conference
June 01 2021 - 8:00AM
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical
company engaged in the discovery and development of novel
immunotherapeutics and vaccines for the treatment and prevention of
infectious diseases and cancer, today announced that the Company’s
Chief Executive Officer, Bill Enright, will be presenting at the
Jefferies Virtual Healthcare Conference on Thursday, June 3 at
11:00 AM EDT.
A live webcast of the presentation can be accessed through the
Events section of the Vaccitech website. Following the live
webcast, a replay will be available at the same location.
About Vaccitech plcVaccitech is a
clinical-stage biopharmaceutical company engaged in the discovery
and development of novel immunotherapeutics and vaccines for the
treatment and prevention of infectious diseases and cancer. The
company’s proprietary platform comprises proprietary modified
simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as
the well-validated Modified Vaccinia Ankara, or MVA, boost vector,
both with demonstrable tolerability profiles and without the
ability to replicate in humans. The combination of a ChAdOx prime
treatment with subsequent MVA boost has consistently generated
significantly higher magnitudes of CD8+ T cells compared with other
technologies and approaches. The company has a broad pipeline of
both clinical and preclinical stage therapeutic programs in solid
tumors and viral infections and prophylactic viral vaccine
programs. Vaccitech co-invented a COVID-19 vaccine with the
University of Oxford, now approved for use in many territories and
exclusively licensed worldwide to AstraZeneca through Oxford
University Innovation, or OUI. Vaccitech is entitled to receive a
share of the milestones and royalty income received by OUI from
AstraZeneca.
Vaccitech Media contacts:Katja Stout, Scius
Communications (EU)Direct: +44 (0) 7789435990Email:
katja@sciuscommunications.com
Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan,
Inc.212-213-0006 ext. 315 / 364Email: rimai@burnsmc.com /
rflamm@burnsmc.com
Henry Hodge, VaccitechDirect: +44 (0) 7533 421 442Email:
henry.hodge@vaccitech.co.uk
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Sep 2023 to Sep 2024